



REATA PHARMACEUTICALS, INC. TO REPORT SECOND QUARTER 2019 FINANCIALS AND TO PROVIDE AN UPDATE ON DEVELOPMENT PROGRAMS ON AUGUST 8, 2019

IRVING, Texas—August 1, 2019—Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, August 8, 2019, at 8:00 a.m. ET before the market opens.

The conference call will be accessible by dialing (844) 348-3946 (toll-free domestic) or (213) 358-0892 (international) using the access code: 7587139. The webcast link is <https://edge.media-server.com/mmc/p/h8xmbyuj>.

Second quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the company's website shortly before the call at <http://reatapharma.com/investors/> and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at <http://reatapharma.com/investors/>.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone methyl (bardoxolone) and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling. **Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.**

Contact:

Reata Pharmaceuticals, Inc.
(972) 865-2219
<http://reatapharma.com>

Investors:

Vinny Jindal
Vice President, Strategy
(469) 374-8721
ir@reatapharma.com
<http://reatapharma.com/contact-us/>

Media:

Matt Middleman, M.D.
LifeSci Public Relations
(646) 627-8384
matt.middleman@lifescipublicrelations.com